用于癌症免疫治疗的双特异性T细胞衔接器
Bispecific T-cell engagers for cancer immunotherapy.
作者信息
Huehls Amelia M, Coupet Tiffany A, Sentman Charles L
机构信息
Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
出版信息
Immunol Cell Biol. 2015 Mar;93(3):290-6. doi: 10.1038/icb.2014.93. Epub 2014 Nov 4.
Bispecific T-cell engagers (BiTEs) are a new class of immunotherapeutic molecules intended for the treatment of cancer. These molecules enhance the patient's immune response to tumors by retargeting T cells to tumor cells. BiTEs are constructed of two single-chain variable fragments (scFv) connected in tandem by a flexible linker. One scFv binds to a T-cell-specific molecule, usually CD3, whereas the second scFv binds to a tumor-associated antigen. This structure and specificity allows a BiTE to physically link a T cell to a tumor cell, ultimately stimulating T-cell activation, tumor killing and cytokine production. BiTEs have been developed, which target several tumor-associated antigens, for a variety of both hematological and solid tumors. Several BiTEs are currently in clinical trials for their therapeutic efficacy and safety. This review examines the salient structural and functional features of BiTEs, as well as the current state of their clinical and preclinical development.
双特异性T细胞衔接器（BiTEs）是一类新型免疫治疗分子，旨在治疗癌症。这些分子通过将T细胞重新靶向肿瘤细胞来增强患者对肿瘤的免疫反应。BiTEs由两个单链可变片段（scFv）通过柔性接头串联连接而成。一个scFv与T细胞特异性分子（通常是CD3）结合，而第二个scFv与肿瘤相关抗原结合。这种结构和特异性使BiTE能够将T细胞与肿瘤细胞物理连接，最终刺激T细胞活化、肿瘤杀伤和细胞因子产生。已经开发出针对多种血液系统肿瘤和实体瘤的几种靶向多种肿瘤相关抗原的BiTEs。目前有几种BiTEs正在进行临床试验以评估其治疗效果和安全性。本综述探讨了BiTEs的显著结构和功能特征，以及它们在临床和临床前开发的现状。
Zotero 插件